ArticleArchives of medical science : AMS2026
P2X7 blockade inhibits the growth of breast cancer in 4T1 breast cancer-bearing mice by NLRP3/caspase 1 pathway.
Article in Archives of medical science : AMS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Therapeutic Significance of NLRP3 Inflammasome in Cancer: Friend or Foe?International journal of molecular sciences · 2024Review
- Novel synthesized ionizable lipid for LNP-mediated P2X7siRNA to inhibit migration and induce apoptosis of breast cancer cells.Purinergic signalling · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The role of P2X7 in the progression of breast cancer remains unclear; hence, it is necessary to investigate whether the P2X7/NLRP3/caspase 1 signalling pathway is associated with the development of breast cancer. Material and methods: 4T1 breast cancer-bearing mice models were developed for P2X7 agonists BzATP and antagonists BBG. The weight of breast cancer tissue among groups was calculated and compared. The cancer tissue was observed by haematoxylin and eosin (HE) staining, and the expression of P2X7, NLRP3, and caspase 1 was examined by immunofluorescence and western blot. Results: The tumour weight and the medullary lymphocytes in the BzATP group were significantly higher than those of the sham and control groups, but the tumour weight and the medullary lymphocytes in the BBG group were significantly lower than those of the sham, control, and BzATP groups. The number of positive P2X7 in the BzATP group was significantly higher than that of other groups, but BBG significantly reduced the number of P2X7. The relative expression level of P2X7 in the BzATP group was significantly higher than that of other groups, but the relative expression level of P2X7 in the BBG group was significantly lower than that of other breast cancer-bearing groups. Conclusions: The blocking of P2X7 can inhibit the growth of breast cancer in 4T1 breast cancer-bearing mice via NLRP3/caspase 1 pathway. Future studies are needed to elucidate the underlying mechanism.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.